Proton pump inhibitor therapy usage and associated hospitalization rates and critical care outcomes of COVID-19 patients
Mehta, Sagar V.
Permanent link to this recordhttp://hdl.handle.net/20.500.12613/8089
MetadataShow full item record
AbstractProton Pump Inhibitors (PPI) are one of the most prescribed medications in the United States. However, PPIs have been shown to increase the risk of enteric infections. Our study aims to evaluate the correlation between PPI and COVID-19 severity. We performed a retrospective cohort study on patients who tested positive for SARS-CoV-2 from March to August 2020. Patients were categorized based on PPI user status. Primary outcomes included need for hospital or ICU admission and 30-day mortality. Secondary outcomes looked to determine the severity of COVID-19 infection and effect of comorbid conditions. 2,594 patients were reviewed. The primary outcomes of our study found that neither active nor past PPI use was associated with increased hospital admission or 30-day mortality following completion of multivariate analysis. Additionally, there was no association between COVID-19 infection and the strength of PPI dosing (low, standard, high). However, the following covariates were independently and significantly associated with increased admission: age, male gender, diabetes, COPD, composite cardiovascular disease, kidney disease, and obesity. The following covariates were associated with increased mortality: age, male gender, COPD, and kidney disease. In conclusion, the high risk features and comorbidities of PPI users were found to have a stronger correlation to severe COVID-19 infection and poor outcomes as opposed to the use of PPI therapy.
CitationShupp, B., Mehta, S.V., Chirayath, S. et al. Proton pump inhibitor therapy usage and associated hospitalization rates and critical care outcomes of COVID-19 patients. Sci Rep 12, 7596 (2022). https://doi.org/10.1038/s41598-022-11680-0
Citation to related workNature Research
Has partScientific Reports, Vol. 12
ADA complianceFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact firstname.lastname@example.org